Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.

skip to main content

Cem Akin, MD, PhD, FAAAAI

Board At-Large Candidate (2022-2026)Akin
Current Employer: University of Michigan
Current Position: Professor

Biographical Statement
Cem Akin, MD, PhD, FAAAAI, is a clinician-scientist and a Professor of Medicine at the University of Michigan, Division of Allergy and Immunology. He obtained his internal medicine training and PhD in microbiology and immunology from the University of Louisville, and completed his fellowship at NIAID/NIH in allergy and clinical immunology. He is recognized for his work on mast cell disorders, including mastocytosis, mast cell activation syndromes and anaphylaxis. As an Associate Professor at Harvard Medical School, he established the first multidisciplinary mastocytosis center at Brigham and Women's Hospital. He is currently leading clinical trials on tyrosine kinase inhibitors in indolent systemic mastocytosis. He has a long history of service to AAAAI, including Chair of the Grant Review Committee, and Chair of the Mechanisms of Asthma and Allergic Inflammation Interest Section. He has served on the Editorial Boards of JACI and Blood, and has written many original and review articles and book chapters for influential titles, including Harrison's and Cecil's Textbooks of Medicine and UptoDate. He is the past President of the Michigan Allergy Society, and currently enjoys teaching fellows, conducting clinical research and seeing a diverse population of allergy patients at the University of Michigan.

Vision Statement
A meaningful contribution to the Board of Directors requires understanding the three pillars of any academic medical specialty as patient care, research, and education. I have been fortunate enough to have significant experience in all of these areas, and I would be honored to bring this experience to the Board, if elected. There are many opportunities and challenges for the allergy specialty in the next decade. I would like to be involved in promoting ways to emphasize the role of the academic institution, not as competitors to smaller private practices, but as hubs of research, innovation and teaching, through partnering with other medical subspecialty organizations. We have to attract the best and the brightest to our specialty. This is only possible through increased visibility of allergy/immunology in medical school curricula and internal medicine, and pediatric departmental educational programs. We should emphasize and explain the exciting development of targeted therapies and biologics to our colleagues and students, while partnering with industry to test and solve the problems related to drug allergy and immunologic reactions presented by this expanding era of new therapeutics.

AAAAI Official Involvement Record
AMPC Programming Workgroup (MAAI), Member, 2016 - 2019
Anaphylaxis Committee, Member, 2002 - 2006
Annual Meeting Program Committee, MAAI Representative, 2015 - 2021
Ethics/Conflict of Interest Committee, Member, 2001 - 2006
Genetics, Molecular Biology & Epidemiology Committee, Member, 2004 - 2009
Grant Review Committee, Chair, 2016 - 2018
Grant Review Committee, Vice Chair, 2014 - 2016
Grant Review Committee, Member, 2006 - 2022
Grant Review Committee, Member, 2002 - 2005
Interest Section Coordinating Committee, MAAI Representative, 2015 - 2021
JACI Editorial Board, Member, 2011 - 2016
Mast Cells Disorders Committee, Member, 2011 - 2026
Mast Cells Disorders Committee, Chair, 2009 - 2011
Mast Cells Disorders Committee, Vice Chair, 2005 - 2009
Mechanisms of Asthma and Allergic Inflammation Int Sec, Chair, 2019 - 2021
Mechanisms of Asthma and Allergic Inflammation Int Sec, Vice Chair, 2017 - 2019
Mechanisms of Asthma and Allergic Inflammation Int Sec, Secretary, 2015 - 2017
Mechanisms of Asthma and Allergic Inflammation Int Sec, Plenary Representative, 2013 - 2015
Mechanisms of Asthma and Allergic Inflammation Int Sec, Plenary Vice Representative, 2011 - 2013
Plenary Workgroup, MAAI Representative, 2013 - 2015
Plenary Workgroup, MAAI Vice Representative, 2011 - 2013
Practice, Diagnostics and Therapeutics Committee, MAAI Representative, 2019 - 2024

Disclosure of Interests
Employer: University of Michigan
Title: Professor

Competing Relationships - $0 - $4,999
Novartis (Ongoing): Consultant: Midostaurin, tyrosine kinase inhibitors, anaphylaxis
Cogent (Ongoing): Consultant: Tyrosine kinase inhibitors, mastocytosis
Aquestive (Ongoing): Consultant: Mast cell activation
Celldex (Ongoing): Consultant: Mastocytosis

Competing Relationships - $5,000 - $25,000
Blueprint (Ongoing): Consultant: Avapritinib/tyrosine kinase inhibitors, mastocytosis
NIH (Ongoing): Royalty: LAD2 cell line
Uptodate (Ongoing): Royalty: Mastocytosis

Competing Relationships - $25,001 - $99,999
Nothing to disclose

Competing Relationships - $100,000 or more
Blueprint (Ongoing): Research Grant: Avapritinib and BLU-263 in indolent systemic mastocytosis

Organizational Interests
European Competence Network on Mastocytosis (Ongoing): Advisor
Michigan Allergy and Asthma Society (Ongoing): At-Large Director
The Mastocytosis Society (Ongoing): Medical Advisory Board

Additional Information
No further information.